PTGX - Protagonist Therapeutics, Inc.
| Previous Close | 7.97 |
| Open | 8.00 |
| Bid | 6.06 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 7.82 - 8.40 |
| 52 Week Range | 5.49 - 23.97 |
| Volume | 139,934 |
| Avg. Volume | 112,662 |
| Market Cap | 195.423M |
| Beta (3Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.32 |
| Earnings Date | Mar 5, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.75 |
- PR Newswire•8 days ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., Jan. 16, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on Jan. 15, 2019, it issued an inducement award to Suneel Gupta, Ph.D., the Company's recently hired Executive Vice President of Clinical Operations and Pharmacology, in accordance with the terms of Dr. Gupta's employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018.
- PR Newswire•15 days ago
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
NEWARK, Calif., Jan. 9, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the first patient has been dosed in the Phase 2 study of PTG-300, an injectable hepcidin mimetic peptide in development for the treatment of patients with beta thalassemia, a rare disease characterized by chronic anemia and iron overload. The study is designed to evaluate the safety and preliminary efficacy of PTG-300 in patients with transfusion-dependent or non-transfusion-dependent beta thalassemia. In a completed Phase 1 study in healthy volunteers, administration of PTG-300 was well tolerated and demonstrated a dose-related and sustained reduction in serum iron levels.
- American City Business Journals•last month
Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more
With hotel stays during next month's J.P. Morgan Healthcare Conference and other nearby events reaching five figures, some wonder if small biotechs are being priced out of San Francisco's big week of meetings with companies and investors.
- Simply Wall St.•last month
Who Has Been Buying Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
- PR Newswire•last month
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
NEWARK, Calif., Dec. 13, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the initiation of dosing in the Phase 1 study of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development for the potential treatment of inflammatory bowel disease. The study is designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic parameters of PN-10943. "This study builds on our previous clinical studies that investigated an oral, gut-restricted approach for the treatment of inflammatory bowel disease," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer.
- PR Newswire•2 months ago
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
NEWARK, Calif. , Dec. 5, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- Benzinga•2 months ago
The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 28) Merck & Co., Inc. (NYSE: MRK ) Ionis Pharmaceuticals ...
- PR Newswire•2 months ago
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
NEWARK, Calif., Nov. 27, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the Company plans to begin clinical development of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the treatment of inflammatory bowel disease (IBD). In preclinical studies, PN-10943 has demonstrated superior properties to PTG-100 as measured by in vitro potency, target engagement based on in vivo pharmacodynamic (PD) readouts of blood receptor occupancy (%RO) and effects on T cell trafficking, and efficacy in disease models of colitis.
- GlobeNewswire•2 months ago
New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current.
- PR Newswire•3 months ago
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14
NEWARK, Calif. , Nov. 7, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- Zacks•3 months ago
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.00% and -3.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Protagonist Therapeutics: 3Q Earnings Snapshot
The Newark, California-based company said it had a loss of 38 cents per share. The biopharmaceutical company posted revenue of $6.1 million in the period. Protagonist Therapeutics shares have dropped 58 ...
- PR Newswire•3 months ago
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
-- Clinical, endoscopic, histologic and biomarker data are consistent with a dose-related clinical efficacy response of PTG-100 in the PROPEL Phase 2 ulcerative colitis study, providing support for PTG-100 ...
- PR Newswire•3 months ago
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
The pharmacokinetic and pharmacodynamic parameters were consistent with the gastrointestinal-restricted design of PTG-200. "Results from this study provide the first clinical data in support of PTG-200 and creates a path forward for its evaluation as a potential first-in-class oral IL-23 pathway based therapeutic for treatment of IBD," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer.
- Zacks•3 months ago
Protagonist Therapeutics (PTGX) Q3 Earnings Preview: What to Know Ahead of the Release
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•3 months ago
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week
-- PTG-100 demonstrates signals of clinical efficacy and is well tolerated -- -- Dose-dependent induction of histologic remission provides further support for PTG-100 as an oral, gut-restricted approach ...
- PR Newswire•4 months ago
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting
NEWARK, Calif. , Oct. 8, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dr. William J. Sandborn will present clinical data from a Phase 2 study of PTG-100, the Company's ...
- PR Newswire•4 months ago
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300
NEWARK, Calif., Sept. 27, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-thalassemia. PTG-300 is an injectable hepcidin mimetic that has been granted Orphan Drug Designation by the FDA for beta-thalassemia, a rare disease characterized by iron overload.
- PR Newswire•4 months ago
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1
NEWARK, Calif. , Sept. 24, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- PR Newswire•4 months ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., Sept. 19, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on Sept. 15, 2018, it issued an inducement award to Carter King, the Company's recently hired Vice President of Business Development, in accordance with the terms of Mr. King's employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018. The inducement award consists of an option to purchase 30,000 shares of Protagonist Therapeutics common stock and has a ten-year term.
- PR Newswire•5 months ago
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
NEWARK, Calif., Sept. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Heart, Lung and Blood Institute of the National Institutes of Health. This award, Number R44HL132702, provides up to $1.45 million over two years to support research aimed at developing the Company's novel hepcidin mimetic clinical drug for the potential treatment of chronic anemia and iron overload in rare blood disorders, including beta-thalassemia. "This grant recognizes the potential benefit of our hepcidin mimetic PTG-300 in the treatment of blood disorders associated with iron metabolism," said David Liu, Ph.D., Protagonist Therapeutics' Head of R&D and Chief Scientific Officer.
- PR Newswire•5 months ago
Protagonist Therapeutics Expands Intellectual Property Portfolio
-- Three issued U.S. patents add to existing protection for clinical drug candidates derived from Protagonist's innovative peptide technology platform -- NEWARK, Calif. , Sept. 6, 2018 /PRNewswire/ -- ...
- PR Newswire•5 months ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., Aug. 17, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on August 15, 2018, it issued an inducement award to Niall Murphy, the Company's recently hired Vice President, Corporate Controller, in accordance with the terms of Mr. Murphy's employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018.
- InvestorPlace•6 months ago
Protagonist Stock Jumps 58% After Re-Review of Test Results
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.
